K. Alves

发表

Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.

E. Schiff, T. Hassanein, M. Yuen, 2022, Journal of hepatology.

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

V. Garg, Katia Alves, R. V. van Heeswijk, 2011, Hepatology.

Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study

T. Hassanein, M. Yuen, D. J. Kim, 2022, Journal of viral hepatitis.

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

N. Enomoto, K. Chayama, T. Pilot‐Matias, 2017, Journal of Gastroenterology.

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Advances in Therapy.

1203 ALL IL28B GENOTYPES HAVE HIGH SVR RATES IN PATIENTS TREATED WITH VX-222 IN COMBINATION WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN IN THE ZENITH STUDY

A. Bisceglie, M. Botfield, M. Koziel, 2012 .

1184 CHARACTERIZATION OF HCV VARIANTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS ADMINISTERED THE COMBINATION OF TVR AND VX-222 IN DUAL ARMS OF ZENITH STUDY

A. Bisceglie, D. Bartels, M. Koziel, 2012 .

Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors

M. Gwinn, E. Delwart, M. Busch, 2002, AIDS.

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Journal of medical virology.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Hepatology.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

H. Yoshiji, K. Chayama, Y. Karino, 2017, Journal of Gastroenterology.

High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil.

K. Page-Shafer, E. Sabino, R. Diaz, 2007, AIDS patient care and STDs.

Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C.

D. Nickle, J. Howe, A. Howe, 2015, Antiviral research.

Risk Factors for Incident HIV Infection Among Anonymous HIV Testing Site Clients in Santos, Brazil: 1996–1999

G. Rutherford, M. Busch, R. Diaz, 2003, Journal of Acquired Immune Deficiency Syndromes.

Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.

J. Albrecht, K. Reddy, B. Bacon, 2013, Gastroenterology.

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial

J. Bradley, P. Kalra, G. Glenn, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil.

G. Cloud, R. Hajjeh, P. Connolly, 2002, The Journal of infectious diseases.

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients

R. Menon, Weihan Zhao, N. Mobashery, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.

S. Dutta, R. Redman, R. Menon, 2015, Clinical therapeutics.

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

N. Enomoto, K. Chayama, T. Pilot‐Matias, 2017, Journal of Gastroenterology.

Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin

V. Garg, Katia Alves, G. Chandorkar, 2012, Journal of clinical pharmacology.

Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

V. Garg, Katia Alves, R. V. van Heeswijk, 2011, Antimicrobial Agents and Chemotherapy.

Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.

E. Schiff, T. Hassanein, M. Yuen, 2022, Journal of hepatology.

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study

E. Schiff, T. Hassanein, M. Yuen, 2020, Journal of Hepatology.

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

V. Garg, Yijun Yang, Katia Alves, 2013, British journal of clinical pharmacology.

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.

T. Pilot‐Matias, S. Lari, D. Cohen, 2018, Annals of hepatology.

HIV type 1 envelope quasispecies in the thymus and lymph Nodes of AIDS patients.

E. Delwart, M. Canzian, K. Alves, 2002, AIDS research and human retroviruses.

Effect of the hepatitis C virus protease inhibitor telaprevir on the 1 pharmacokinetics of amlodipine and atorvastatin 2 3 4

V. Garg, R. Heeswijk, Frances Smith, 2011 .

Infectious diarrhea in autologous stem cell transplantation: high prevalence of coccidia in a South American center

L. Costa, A. E. Neto, J. Chebli, 2018, Hematology, transfusion and cell therapy.

Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients

R. Menon, Weihan Zhao, Katia Alves, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection

E. Schiff, T. Hassanein, D. Dieterich, 2020 .

VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection

Tara L. Kieffer, E. Gane, M. Sulkowski, 2014, European journal of gastroenterology & hepatology.